Did you ever ask yourself one of the following questions?: “…a significant difference (p=0.002) was observed between the two groups…” What does this mean? What exactly is a p-value and
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company
Specialist pharmaceutical company Open Orphan said its subsidiary Venn Life Sciences has agreed a contract renewal deal with a major global pharmaceutical client worth £1.5m over two years. The renewed
Open Orphan (LON:ORPH) has announced that data from the first-in-human Phase I clinical study evaluating the safety, immunogenicity, and in vitro efficacy of AGS-v PLUS, Imutex Limited’s mosquito saliva vaccine candidate against arboviral diseases,
Specialist pharmaceutical services clinical research company Open Orphan said its hVIVO subsidiary has signed a £5.1m contract with a biopharmaceutical company to use its respiratory syncytial virus (RSV) human challenge
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO , a subsidiary of Open
Venn Life Sciences, a subsidiary of Irish-led vaccine research firm Open Orphan, has signed a million-euro contract renewal with an unnamed global pharmaceutical client. The contract – worth worth £1.5m
Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that Venn Life Sciences, a subsidiary
A London hotel repurposed into a lab is preparing to be the first in the world to infect humans with Covid. The Whitechapel Hotel in the city’s East End is
Cathal Friel, Executive Chairman and Founder of Open Orphan speaks with RTE Radio 1’s Claire Bryne. https://www.rte.ie/radio/radio1/clips/22024351/ Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
